Along these lines, combination treatment of pancreatic cancer cells with absent (or nearly undetectable) MUC16 expression did not result in a differential killing profile between the two TRAIL drugs (Supplementary Figure S3). This evidence concerns the gene MUC16 and pancreatic neoplasm.